•
Sep 30, 2021

Tenet Healthcare Q3 2021 Earnings Report

Tenet Healthcare's financial performance in Q3 2021 demonstrated significant improvement compared to the previous year. The company reported a substantial increase in net income and adjusted EBITDA, driven by strong performance across its operating segments.

Key Takeaways

Tenet Healthcare reported a net income of $448 million, or $4.12 per diluted share, compared to a net loss of $197 million, or $1.87 per share, in Q3 2020. Adjusted EBITDA reached $855 million, up from $551 million in the prior year. The company raised its full-year 2021 financial guidance, reflecting confidence in continued growth and strong cash flow generation.

Net income from continuing operations available to common shareholders was $448 million in Q3 2021, a significant increase from the $197 million net loss in Q3 2020.

Consolidated Adjusted EBITDA increased to $855 million in Q3 2021, compared to $551 million in Q3 2020.

Diluted earnings per share from continuing operations was $4.12 in Q3 2021, compared to a loss per share of $1.87 in Q3 2020; Adjusted diluted earnings per share from continuing operations of $1.99 in Q3 2021 compared to $0.64 in Q3 2020

Tenet raised its full-year 2021 outlook for net income, Adjusted EBITDA, and adjusted diluted earnings per share, indicating strong financial performance and positive trajectory.

Total Revenue
$4.89B
Previous year: $4.56B
+7.4%
EPS
$4.2
Previous year: -$1.87
-324.6%
Admissions growth
2.6%
Gross Profit
$4.07B
Previous year: $3.77B
+7.8%
Cash and Equivalents
$2.29B
Previous year: $3.3B
-30.5%
Free Cash Flow
$321M
Previous year: $507M
-36.7%
Total Assets
$25.9B
Previous year: $26.2B
-1.0%

Tenet Healthcare

Tenet Healthcare

Tenet Healthcare Revenue by Segment

Forward Guidance

Tenet Healthcare provided its outlook for FY 2021, projecting net operating revenues between $19.5 billion and $19.8 billion, and Adjusted EBITDA between $3.275 billion and $3.325 billion.

Positive Outlook

  • Net operating revenues are projected to be between $19.5 billion and $19.8 billion.
  • Adjusted EBITDA is expected to be in the range of $3.275 billion to $3.325 billion.
  • Diluted income per common share from continuing operations is forecasted to be between $7.09 and $7.50.
  • Adjusted diluted earnings per share from continuing operations are anticipated to be between $6.15 and $6.38.
  • Adjusted free cash flow is projected to be between $650 million and $850 million.

Challenges Ahead

  • Interest expense is expected to be between $915 million and $925 million.
  • Capital expenditures are projected to be between $675 million and $725 million.
  • NCI cash distributions are estimated to be between $450 million and $470 million.
  • Depreciation and amortization expenses are expected to be between $860 million and $870 million.
  • Effective tax rate is estimated to be around 18%.

Revenue & Expenses

Visualization of income flow from segment revenue to net income